metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population
versus Standard of Care (SoC)
	durvalumab plus tremelimumab
	MYSTIC (DT ; all population), 2020 JAMA Oncol 2020 May 1;6(5):661-674. NCT02453282	RCT	mNSCLC - L1 - all population	durvalumab and tremelimumab	platinum-based doublet chemotherapy	first-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%	372 / 372	some concern	inconclusive	no statistically significant result
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus Standard of Care (SoC)
	durvalumab plus tremelimumab
	MYSTIC (DT ; PDL1>25%), 2020 JAMA Oncol 2020 May 1;6(5):661-674. NCT02453282	RCT	mNSCLC - L1 - PDL1 positive	durvalumab and tremelimumab	platinum-based doublet chemotherapy	first-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%	163 / 162	some concern	inconclusive	inconclusive 15 % decrease in deaths (OS) (PE) inconclusive 5 % increase in progression or deaths (PFS) (PE)
mNSCLC - L2 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 negative
versus Standard of Care (SoC)
	durvalumab plus tremelimumab
	ARCTIC (DT ; study B ; PDL1<25%), 2020 Clin Lung Cancer 2016; 17:232-236.e1 Ann Oncol 2020 May;31(5):609-618. NCT02352948	RCT	mNSCLC - L2 - PDL1 negative	durvalumab plus tremelimumab	standard of care : erlotinib, gemcitabine or vinorelbine	patients with PD-L1 positive locally advanced or metastatic non small cell lung cancer who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for stage IIIB/IV locally advanced or mNSCLC;	174 / 118	some concern	inconclusive	inconclusive 20 % decrease in deaths (OS) (PE) inconclusive 23 % decrease in progression or deaths (PFS) (PE)

Study

study type

Pathology

Patients

sample sizes

ROB

Results

NCT02453282

RCT

mNSCLC - L1 - all population

durvalumab and tremelimumab

platinum-based doublet chemotherapy

first-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%

372 / 372

NCT02453282

RCT

mNSCLC - L1 - PDL1 positive

durvalumab and tremelimumab

platinum-based doublet chemotherapy

first-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%

163 / 162

inconclusive 15 % decrease in deaths (OS) (PE)
inconclusive 5 % increase in progression or deaths (PFS) (PE)

NCT02352948

RCT

mNSCLC - L2 - PDL1 negative

durvalumab plus tremelimumab

standard of care : erlotinib, gemcitabine or vinorelbine

patients with PD-L1 positive locally advanced or metastatic non small cell lung cancer who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for stage IIIB/IV locally advanced or mNSCLC;

174 / 118

inconclusive 20 % decrease in deaths (OS) (PE)
inconclusive 23 % decrease in progression or deaths (PFS) (PE)

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

versus Standard of Care (SoC)

durvalumab plus tremelimumab

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)

durvalumab plus tremelimumab

mNSCLC - L2 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 negative

versus Standard of Care (SoC)

durvalumab plus tremelimumab